Background: Currently, there are no specific drugs or targets available for the treatment of tendinopathy. However, inflammation has recently been found to play a pivotal role in tendinopathy progression, thereby identifying it as a potential therapeutic target. Carpaine (CA) exhibits potential anti-inflammatory pharmacological properties and may offer a therapeutic option for tendinopathy.
Purpose: This study aimed to investigate the effectiveness of CA in addressing tendinopathy and uncovering its underlying mechanisms.
Methods: Herein, the efficacy of CA by local administration in vivo in comparison to the first-line drug indomethacin was evaluated in a mouse collagenase-induced tendinopathy (CIT) model. Furthermore, IL-1β induced a simulated pathological inflammatory microenvironment in tenocytes to investigate its underlying mechanisms in vitro. Further confirmation experiments were performed by overexpressing or knocking down the selective targets of CA in vivo.
Results: The findings demonstrated that CA was dose-dependent in treating tendinopathy and that the high-dose group outperformed the first-line drug indomethacin. Mechanistically, CA selectively bound to and enhanced the activity of the E3 ubiquitin ligase LRSAM1 in tendinopathy. This effect mediated the ubiquitination of p65 at lysine 93, subsequently promoting its proteasomal degradation. As a result, the NF-κB pathway was inactivated, leading to a reduction in inflammation of tendinopathy. Consequently, CA effectively mitigated the progression of tendinopathy. Moreover, the LRSAM1 overexpression demonstrated effectiveness in mitigating the tendinopathy progression and its knockdown abolished the therapeutic effects of CA.
Conclusion: CA attenuates the progression of tendinopathy by promoting the ubiquitin-proteasomal degradation of p65 via increasing the enzyme activity of LRSAM1. The exploration of LRSAM1 has also unveiled a new potential target for treating tendinopathy based on the ubiquitin-proteasomal pathway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phymed.2023.155323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Achilles Tendon Mechanical But Not Morphological Properties Change with Rehabilitation in Patients with Chronic Midportion Achilles Tendinopathy.
Med Sci Sports Exerc
November 2024
Human Movement Biomechanics research group, Department of Movement Science, KU Leuven, BELGIUM.
Purpose: Achilles tendinopathy (AT) is associated with altered tendon's morphological and mechanical properties, yet it is unclear whether these properties are reversed upon mechanical loading to promote tendon healing. This study aims to determine the extent to which pathological tendon's morphological and mechanical properties adapt throughout a 12-week eccentric rehabilitation protocol.
Methods: Forty participants with midportion AT were recruited and participated in a 12-week eccentric rehabilitation program.
Sirolimus as a repurposed drug for tendinopathy: A systems biology approach combining computational and experimental methods.
Comput Biol Med
January 2025
Department of Orthopedics, Affiliated Huzhou Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Huzhou, China; Department of Sports Medicine & Orthopedic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of sports medicine, Zhejiang University, Hangzhou, China; Orthopedics Research Institute of Zhejiang University, Hangzhou, China; Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, China; Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou, China. Electronic address:
Background: Effective drugs for tendinopathy are lacking, resulting in significant morbidity and re-tearing rate after operation. Applying systems biology to identify new applications for current pharmaceuticals can decrease the duration, expenses, and likelihood of failure associated with the development of new drugs.
Methods: We identify tendinopathy signature genes employing a transcriptomics database encompassing 154 clinical tendon samples.
Treatment options for Achilles tendinopathy: a scoping review of preclinical studies.
PeerJ
January 2025
University of Amsterdam, Amsterdam, Netherlands.
Background: Achilles tendinopathy (AT) management can be difficult, given the paucity of effective treatment options and the degenerative nature of the condition. Innovative therapies for Achilles tendinopathy are therefore direly needed. New therapeutic developments predominantly begin with preclinical animal and in vitro studies to understand the effects at the molecular level and to evaluate toxicity.
View Article and Find Full Text PDFHeavy slow resistance training, radial extracorporeal shock wave therapy or advice for patients with tennis elbow in the Norwegian secondary care: a randomised controlled feasibility trial.
BMJ Open
December 2024
Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway.
Objectives: To evaluate the feasibility of recruitment, appointment adherence, intervention compliance, acceptance and comprehensibility, in addition to retention rate and data completeness. An ancillary aim was to describe within-group changes in the secondary outcome measures (patient-reported and performance-based).
Design: A single-centre, three-armed, randomised controlled feasibility trial with a parallel design, with follow-up after 3 and 6 months.
Efficacy of Platelet-Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome: A Double-Blinded Randomized Controlled Trial.
J Bone Joint Surg Am
January 2025
Northumbria Healthcare NHS Foundation Trust, Northumberland, United Kingdom.
Background: Greater trochanteric pain syndrome (GTPS) is a painful condition that can impair a patient's quality of life. If nonoperative measures fail, progressively more invasive treatment options may be required. This clinical trial aimed to evaluate the effectiveness of ultrasound-guided leukocyte-rich platelet-rich plasma (LR-PRP) injections in the treatment of refractory GTPS caused by bursitis and/or gluteal tendinopathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!